Associations between the triglyceride-glucose index and cardiovascular disease in over 150,000 cancer survivors: a population-based cohort study
Background The prevention of subsequent cardiovascular disease (CVD) is an essential part of cancer survivorship care. We conducted the present study to investigate the association between the TyG index (a surrogate marker of insulin resistance) and the risk of cardiovascular disease (CVD) events in...
Saved in:
| Published in | Cardiovascular diabetology Vol. 21; no. 1; pp. 52 - 10 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
16.04.2022
BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1475-2840 1475-2840 |
| DOI | 10.1186/s12933-022-01490-z |
Cover
| Abstract | Background
The prevention of subsequent cardiovascular disease (CVD) is an essential part of cancer survivorship care. We conducted the present study to investigate the association between the TyG index (a surrogate marker of insulin resistance) and the risk of cardiovascular disease (CVD) events in cancer survivors.
Methods
Adult cancer patients, who underwent routine health examinations during 2009–2010 and were survived for more than 5 years as of January 1, 2011, were followed for hospitalization of CVD (either ischemic heart disease, stroke, or heart failure) until December 2020. Cox model was used to calculate hazard ratios associated with baseline TyG index (log
e
[fasting triglyceride (mg) × fasting glucose (mg)/2]) for the CVD hospitalization.
Results
A total of 155,167 cancer survivors (mean age 59.9 ± 12.0 years, female 59.1%) were included in this study. A graded positive association was observed between TyG and CVD hospitalization. An 8% elevated risk for CVD hospitalization was observed for a TyG index of 8-8.4 (aHR 1.08 [95% CI 1.01–1.14]); 10% elevated risk for a TyG index of 8.5–8.9 (aHR 1.10 [95% CI 1.03–1.17]); 23% elevated risk for a TyG index of 9.0-9.4 (aHR 1.23 [95% CI 1.15–1.31]); 34% elevated risk for a TyG index of 9.5–9.9 (aHR 1.34 [95% CI 1.23–1.47]); and 55% elevated risk for a TyG index
≥
10 compared to the reference group (TyG index < 8). Per 1-unit increase in the TyG index, a 16% increase in CVD hospitalization and a 45% increase in acute myocardial infarction hospitalization were demonstrated. Graded positive associations were evident for atherosclerotic CVD subtypes, such as ischemic heart disease, acute myocardial infarction, and ischemic stroke, but not for hemorrhagic stroke or heart failure.
Conclusions
The TyG index may serve as a simple surrogate marker for the risk stratification of future CVD events, particularly atherosclerotic subtypes, in cancer survivors. |
|---|---|
| AbstractList | The prevention of subsequent cardiovascular disease (CVD) is an essential part of cancer survivorship care. We conducted the present study to investigate the association between the TyG index (a surrogate marker of insulin resistance) and the risk of cardiovascular disease (CVD) events in cancer survivors.BACKGROUNDThe prevention of subsequent cardiovascular disease (CVD) is an essential part of cancer survivorship care. We conducted the present study to investigate the association between the TyG index (a surrogate marker of insulin resistance) and the risk of cardiovascular disease (CVD) events in cancer survivors.Adult cancer patients, who underwent routine health examinations during 2009-2010 and were survived for more than 5 years as of January 1, 2011, were followed for hospitalization of CVD (either ischemic heart disease, stroke, or heart failure) until December 2020. Cox model was used to calculate hazard ratios associated with baseline TyG index (loge [fasting triglyceride (mg) × fasting glucose (mg)/2]) for the CVD hospitalization.METHODSAdult cancer patients, who underwent routine health examinations during 2009-2010 and were survived for more than 5 years as of January 1, 2011, were followed for hospitalization of CVD (either ischemic heart disease, stroke, or heart failure) until December 2020. Cox model was used to calculate hazard ratios associated with baseline TyG index (loge [fasting triglyceride (mg) × fasting glucose (mg)/2]) for the CVD hospitalization.A total of 155,167 cancer survivors (mean age 59.9 ± 12.0 years, female 59.1%) were included in this study. A graded positive association was observed between TyG and CVD hospitalization. An 8% elevated risk for CVD hospitalization was observed for a TyG index of 8-8.4 (aHR 1.08 [95% CI 1.01-1.14]); 10% elevated risk for a TyG index of 8.5-8.9 (aHR 1.10 [95% CI 1.03-1.17]); 23% elevated risk for a TyG index of 9.0-9.4 (aHR 1.23 [95% CI 1.15-1.31]); 34% elevated risk for a TyG index of 9.5-9.9 (aHR 1.34 [95% CI 1.23-1.47]); and 55% elevated risk for a TyG index ≥ 10 compared to the reference group (TyG index < 8). Per 1-unit increase in the TyG index, a 16% increase in CVD hospitalization and a 45% increase in acute myocardial infarction hospitalization were demonstrated. Graded positive associations were evident for atherosclerotic CVD subtypes, such as ischemic heart disease, acute myocardial infarction, and ischemic stroke, but not for hemorrhagic stroke or heart failure.RESULTSA total of 155,167 cancer survivors (mean age 59.9 ± 12.0 years, female 59.1%) were included in this study. A graded positive association was observed between TyG and CVD hospitalization. An 8% elevated risk for CVD hospitalization was observed for a TyG index of 8-8.4 (aHR 1.08 [95% CI 1.01-1.14]); 10% elevated risk for a TyG index of 8.5-8.9 (aHR 1.10 [95% CI 1.03-1.17]); 23% elevated risk for a TyG index of 9.0-9.4 (aHR 1.23 [95% CI 1.15-1.31]); 34% elevated risk for a TyG index of 9.5-9.9 (aHR 1.34 [95% CI 1.23-1.47]); and 55% elevated risk for a TyG index ≥ 10 compared to the reference group (TyG index < 8). Per 1-unit increase in the TyG index, a 16% increase in CVD hospitalization and a 45% increase in acute myocardial infarction hospitalization were demonstrated. Graded positive associations were evident for atherosclerotic CVD subtypes, such as ischemic heart disease, acute myocardial infarction, and ischemic stroke, but not for hemorrhagic stroke or heart failure.The TyG index may serve as a simple surrogate marker for the risk stratification of future CVD events, particularly atherosclerotic subtypes, in cancer survivors.CONCLUSIONSThe TyG index may serve as a simple surrogate marker for the risk stratification of future CVD events, particularly atherosclerotic subtypes, in cancer survivors. Abstract Background The prevention of subsequent cardiovascular disease (CVD) is an essential part of cancer survivorship care. We conducted the present study to investigate the association between the TyG index (a surrogate marker of insulin resistance) and the risk of cardiovascular disease (CVD) events in cancer survivors. Methods Adult cancer patients, who underwent routine health examinations during 2009–2010 and were survived for more than 5 years as of January 1, 2011, were followed for hospitalization of CVD (either ischemic heart disease, stroke, or heart failure) until December 2020. Cox model was used to calculate hazard ratios associated with baseline TyG index (loge [fasting triglyceride (mg) × fasting glucose (mg)/2]) for the CVD hospitalization. Results A total of 155,167 cancer survivors (mean age 59.9 ± 12.0 years, female 59.1%) were included in this study. A graded positive association was observed between TyG and CVD hospitalization. An 8% elevated risk for CVD hospitalization was observed for a TyG index of 8-8.4 (aHR 1.08 [95% CI 1.01–1.14]); 10% elevated risk for a TyG index of 8.5–8.9 (aHR 1.10 [95% CI 1.03–1.17]); 23% elevated risk for a TyG index of 9.0-9.4 (aHR 1.23 [95% CI 1.15–1.31]); 34% elevated risk for a TyG index of 9.5–9.9 (aHR 1.34 [95% CI 1.23–1.47]); and 55% elevated risk for a TyG index ≥ 10 compared to the reference group (TyG index < 8). Per 1-unit increase in the TyG index, a 16% increase in CVD hospitalization and a 45% increase in acute myocardial infarction hospitalization were demonstrated. Graded positive associations were evident for atherosclerotic CVD subtypes, such as ischemic heart disease, acute myocardial infarction, and ischemic stroke, but not for hemorrhagic stroke or heart failure. Conclusions The TyG index may serve as a simple surrogate marker for the risk stratification of future CVD events, particularly atherosclerotic subtypes, in cancer survivors. Background The prevention of subsequent cardiovascular disease (CVD) is an essential part of cancer survivorship care. We conducted the present study to investigate the association between the TyG index (a surrogate marker of insulin resistance) and the risk of cardiovascular disease (CVD) events in cancer survivors. Methods Adult cancer patients, who underwent routine health examinations during 2009–2010 and were survived for more than 5 years as of January 1, 2011, were followed for hospitalization of CVD (either ischemic heart disease, stroke, or heart failure) until December 2020. Cox model was used to calculate hazard ratios associated with baseline TyG index (loge [fasting triglyceride (mg) × fasting glucose (mg)/2]) for the CVD hospitalization. Results A total of 155,167 cancer survivors (mean age 59.9 ± 12.0 years, female 59.1%) were included in this study. A graded positive association was observed between TyG and CVD hospitalization. An 8% elevated risk for CVD hospitalization was observed for a TyG index of 8-8.4 (aHR 1.08 [95% CI 1.01–1.14]); 10% elevated risk for a TyG index of 8.5–8.9 (aHR 1.10 [95% CI 1.03–1.17]); 23% elevated risk for a TyG index of 9.0-9.4 (aHR 1.23 [95% CI 1.15–1.31]); 34% elevated risk for a TyG index of 9.5–9.9 (aHR 1.34 [95% CI 1.23–1.47]); and 55% elevated risk for a TyG index ≥ 10 compared to the reference group (TyG index < 8). Per 1-unit increase in the TyG index, a 16% increase in CVD hospitalization and a 45% increase in acute myocardial infarction hospitalization were demonstrated. Graded positive associations were evident for atherosclerotic CVD subtypes, such as ischemic heart disease, acute myocardial infarction, and ischemic stroke, but not for hemorrhagic stroke or heart failure. Conclusions The TyG index may serve as a simple surrogate marker for the risk stratification of future CVD events, particularly atherosclerotic subtypes, in cancer survivors. The prevention of subsequent cardiovascular disease (CVD) is an essential part of cancer survivorship care. We conducted the present study to investigate the association between the TyG index (a surrogate marker of insulin resistance) and the risk of cardiovascular disease (CVD) events in cancer survivors. Adult cancer patients, who underwent routine health examinations during 2009-2010 and were survived for more than 5 years as of January 1, 2011, were followed for hospitalization of CVD (either ischemic heart disease, stroke, or heart failure) until December 2020. Cox model was used to calculate hazard ratios associated with baseline TyG index (log [fasting triglyceride (mg) × fasting glucose (mg)/2]) for the CVD hospitalization. A total of 155,167 cancer survivors (mean age 59.9 ± 12.0 years, female 59.1%) were included in this study. A graded positive association was observed between TyG and CVD hospitalization. An 8% elevated risk for CVD hospitalization was observed for a TyG index of 8-8.4 (aHR 1.08 [95% CI 1.01-1.14]); 10% elevated risk for a TyG index of 8.5-8.9 (aHR 1.10 [95% CI 1.03-1.17]); 23% elevated risk for a TyG index of 9.0-9.4 (aHR 1.23 [95% CI 1.15-1.31]); 34% elevated risk for a TyG index of 9.5-9.9 (aHR 1.34 [95% CI 1.23-1.47]); and 55% elevated risk for a TyG index ≥ 10 compared to the reference group (TyG index < 8). Per 1-unit increase in the TyG index, a 16% increase in CVD hospitalization and a 45% increase in acute myocardial infarction hospitalization were demonstrated. Graded positive associations were evident for atherosclerotic CVD subtypes, such as ischemic heart disease, acute myocardial infarction, and ischemic stroke, but not for hemorrhagic stroke or heart failure. The TyG index may serve as a simple surrogate marker for the risk stratification of future CVD events, particularly atherosclerotic subtypes, in cancer survivors. Background The prevention of subsequent cardiovascular disease (CVD) is an essential part of cancer survivorship care. We conducted the present study to investigate the association between the TyG index (a surrogate marker of insulin resistance) and the risk of cardiovascular disease (CVD) events in cancer survivors. Methods Adult cancer patients, who underwent routine health examinations during 2009–2010 and were survived for more than 5 years as of January 1, 2011, were followed for hospitalization of CVD (either ischemic heart disease, stroke, or heart failure) until December 2020. Cox model was used to calculate hazard ratios associated with baseline TyG index (log e [fasting triglyceride (mg) × fasting glucose (mg)/2]) for the CVD hospitalization. Results A total of 155,167 cancer survivors (mean age 59.9 ± 12.0 years, female 59.1%) were included in this study. A graded positive association was observed between TyG and CVD hospitalization. An 8% elevated risk for CVD hospitalization was observed for a TyG index of 8-8.4 (aHR 1.08 [95% CI 1.01–1.14]); 10% elevated risk for a TyG index of 8.5–8.9 (aHR 1.10 [95% CI 1.03–1.17]); 23% elevated risk for a TyG index of 9.0-9.4 (aHR 1.23 [95% CI 1.15–1.31]); 34% elevated risk for a TyG index of 9.5–9.9 (aHR 1.34 [95% CI 1.23–1.47]); and 55% elevated risk for a TyG index ≥ 10 compared to the reference group (TyG index < 8). Per 1-unit increase in the TyG index, a 16% increase in CVD hospitalization and a 45% increase in acute myocardial infarction hospitalization were demonstrated. Graded positive associations were evident for atherosclerotic CVD subtypes, such as ischemic heart disease, acute myocardial infarction, and ischemic stroke, but not for hemorrhagic stroke or heart failure. Conclusions The TyG index may serve as a simple surrogate marker for the risk stratification of future CVD events, particularly atherosclerotic subtypes, in cancer survivors. |
| ArticleNumber | 52 |
| Author | Yi, Jee-Jeon Han, Seongwoo An, Sang Joon Jung, Mi-Hyang Ihm, Sang-Hyun Ryu, Kyu-Hyung Youn, Ho-Joong Yi, Sang-Wook Jung, Hae Ok |
| Author_xml | – sequence: 1 givenname: Mi-Hyang surname: Jung fullname: Jung, Mi-Hyang organization: Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Catholic Research Institute for Intractable Cardiovascular Disease College of Medicine , The Catholic University of Korea – sequence: 2 givenname: Sang-Wook surname: Yi fullname: Yi, Sang-Wook email: flyhigh@cku.ac.kr organization: Department of Preventive Medicine and Public Health, College of Medicine, Catholic Kwandong University – sequence: 3 givenname: Sang Joon surname: An fullname: An, Sang Joon organization: Department of Neurology , International St. Mary’s Hospital Catholic Kwandong University College of Medicine – sequence: 4 givenname: Jee-Jeon surname: Yi fullname: Yi, Jee-Jeon organization: Institute for Occupational and Environmental Health, Catholic Kwandong University – sequence: 5 givenname: Sang-Hyun surname: Ihm fullname: Ihm, Sang-Hyun organization: Catholic Research Institute for Intractable Cardiovascular Disease College of Medicine , The Catholic University of Korea , Division of Cardiology, Department of Internal Medicine, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea – sequence: 6 givenname: Seongwoo surname: Han fullname: Han, Seongwoo organization: Cardiovascular Center, Dongtan Sacred Heart Hospital Hallym University College of Medicine – sequence: 7 givenname: Kyu-Hyung surname: Ryu fullname: Ryu, Kyu-Hyung organization: Cardiovascular Center, Dongtan Sacred Heart Hospital Hallym University College of Medicine – sequence: 8 givenname: Hae Ok surname: Jung fullname: Jung, Hae Ok organization: Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Catholic Research Institute for Intractable Cardiovascular Disease College of Medicine , The Catholic University of Korea – sequence: 9 givenname: Ho-Joong surname: Youn fullname: Youn, Ho-Joong organization: Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Catholic Research Institute for Intractable Cardiovascular Disease College of Medicine , The Catholic University of Korea |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35429972$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kk1vFCEYxyemxr7oF_BgSLx4cPQBhp3Bg0nT-NKkiRc9Ewae3WUzCyswo9tP4UeW3a217aEnCPz-Px7gOa2OfPBYVS8pvKO0m71PlEnOa2CsBtpIqK-fVCe0aUXNugaO7syPq9OUVgC07Wb0WXXMRcOkbNlJ9ec8pWCczi74RHrMvxA9yUskObrFsDUYncV6MYwmJCTOW_xNtLfE6GhdmHQy46AjsS6h3gMkTBgJFfAWAArmi4KkMU5uCjF9IJpswqZkdifWfckUV1iGmEnKo90-r57O9ZDwxc14Vv34_On7xdf66tuXy4vzq9rMoM215BItFRb5TDZz0xnkTDIwFGk3bwQ30HHRUdoimtYC9lwbw61lRlgBnPGz6vLgtUGv1Ca6tY5bFbRT-4UQF0rH7MyASjJB55JJaEE3Qvad7svDty3nPfC-aYrr48G1Gfs1WoM-Rz3ck97f8W6pFmFSEigvxiJ4cyOI4eeIKau1SwaHQXsMY1JsJhiwTgpa0NcP0FUYoy9PtaOobDrGdtSruxXdlvLv4wvADoCJIaWI81uEgtp1lzp0lyrdpfbdpa5LqHsQMi7vP7Lcyg2PR_khmso5foHxf9mPpP4CUgjmAg |
| CitedBy_id | crossref_primary_10_1186_s12933_023_01866_9 crossref_primary_10_51789_cmsj_2024_4_e1 crossref_primary_10_1016_j_pmedr_2024_102760 crossref_primary_10_1097_MD_0000000000035886 crossref_primary_10_1186_s12933_023_01973_7 crossref_primary_10_1186_s12933_023_02018_9 crossref_primary_10_1186_s13040_024_00363_3 crossref_primary_10_3389_fendo_2023_1280221 crossref_primary_10_1186_s12877_023_04041_7 crossref_primary_10_1093_ehjqcco_qcae055 crossref_primary_10_1093_eurjpc_zwac241 crossref_primary_10_1161_JAHA_123_029362 crossref_primary_10_1007_s13760_022_02060_6 crossref_primary_10_12677_ACM_2024_142440 crossref_primary_10_1016_j_numecd_2022_11_004 crossref_primary_10_51789_cmsj_2024_4_e10 crossref_primary_10_1186_s13098_023_01009_w crossref_primary_10_3389_fendo_2024_1371393 crossref_primary_10_1186_s12933_023_01924_2 crossref_primary_10_1007_s44178_023_00058_5 crossref_primary_10_2147_DMSO_S490585 crossref_primary_10_3389_fendo_2023_1259062 crossref_primary_10_3389_fnut_2022_1050643 crossref_primary_10_1186_s44348_024_00014_5 crossref_primary_10_1016_j_ijcrp_2024_200315 crossref_primary_10_1186_s12986_024_00819_7 |
| Cites_doi | 10.1016/j.diabres.2011.05.030 10.1097/EDE.0000000000000394 10.2337/dc21-0429 10.1089/met.2008.0034 10.1038/s41598-019-43776-5 10.1186/s12916-020-01824-2 10.1093/eurjpc/zwab230 10.1186/s12933-021-01238-1 10.3988/jcn.2016.12.1.42 10.1002/hon.2402 10.1210/er.2018-00141 10.1161/CIR.0000000000000556 10.1016/j.ypmed.2016.01.022 10.1210/jc.2010-0288 10.1016/j.atherosclerosis.2015.07.033 10.1200/JCO.2006.06.6340 10.2337/diabetes.53.11.2735 10.1016/j.diabet.2021.101246 10.1200/JCO.2015.64.0409 10.5551/jat.59840 10.1007/s00125-020-05160-1 10.3322/caac.21654 10.1161/CIR.0000000000000641 10.2337/dc18-1920 10.1111/eci.12583 10.1186/s12933-018-0692-1 10.1016/j.ijcard.2020.04.080 10.1186/s12933-017-0589-4 10.1007/s12020-021-02862-3 10.1186/s12933-020-01031-6 10.2310/JIM.0000000000000044 10.1093/eurheartj/ehz766 10.1186/s12933-020-01121-5 10.1186/s12933-020-01210-5 10.4143/crt.2019.138 10.1001/jamacardio.2016.3841 10.1016/j.cardfail.2009.03.001 10.1186/s13098-018-0376-8 10.1016/j.currproblcancer.2020.100615 10.1161/CIRCULATIONAHA.105.563213 10.3322/caac.21235 10.1016/j.jchf.2013.07.006 10.1186/s12933-020-01186-2 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2022 2022. The Author(s). 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2022 – notice: 2022. The Author(s). – notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7T5 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12933-022-01490-z |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Immunology Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database MEDLINE |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature Open Access Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1475-2840 |
| EndPage | 10 |
| ExternalDocumentID | oai_doaj_org_article_9251f929070a459b8ab2937733b03b44 PMC9013459 35429972 10_1186_s12933_022_01490_z |
| Genre | Journal Article |
| GroupedDBID | --- 0R~ 29B 2WC 53G 5GY 5VS 6J9 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB AAYXX ALIPV CITATION CGR CUY CVF ECM EIF NPM 3V. 7T5 7XB 8FK AZQEC DWQXO H94 K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c607t-939ed15de3694fc8ce32920c1e18f453c08358117eec7d0eb3acc3dd2c5d50323 |
| IEDL.DBID | 7X7 |
| ISSN | 1475-2840 |
| IngestDate | Wed Aug 27 01:31:16 EDT 2025 Thu Aug 21 18:15:54 EDT 2025 Fri Sep 05 02:54:26 EDT 2025 Fri Jul 25 03:03:33 EDT 2025 Thu Apr 03 07:03:54 EDT 2025 Tue Jul 01 04:19:55 EDT 2025 Thu Apr 24 23:12:31 EDT 2025 Sat Sep 06 07:28:52 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Prevention Cardio-oncology Survivorship Cardiovascular diseases Cancer |
| Language | English |
| License | 2022. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c607t-939ed15de3694fc8ce32920c1e18f453c08358117eec7d0eb3acc3dd2c5d50323 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://www.proquest.com/docview/2651948221?pq-origsite=%requestingapplication% |
| PMID | 35429972 |
| PQID | 2651948221 |
| PQPubID | 42570 |
| PageCount | 10 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_9251f929070a459b8ab2937733b03b44 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9013459 proquest_miscellaneous_2652028951 proquest_journals_2651948221 pubmed_primary_35429972 crossref_primary_10_1186_s12933_022_01490_z crossref_citationtrail_10_1186_s12933_022_01490_z springer_journals_10_1186_s12933_022_01490_z |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-04-16 |
| PublicationDateYYYYMMDD | 2022-04-16 |
| PublicationDate_xml | – month: 04 year: 2022 text: 2022-04-16 day: 16 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Cardiovascular diabetology |
| PublicationTitleAbbrev | Cardiovasc Diabetol |
| PublicationTitleAlternate | Cardiovasc Diabetol |
| PublicationYear | 2022 |
| Publisher | BioMed Central BMC |
| Publisher_xml | – name: BioMed Central – name: BMC |
| References | K Park (1490_CR10) 2019; 42 JA Kim (1490_CR41) 2006; 113 RL Siegel (1490_CR35) 2021; 71 L Sanchez-Inigo (1490_CR22) 2016; 46 LE Simental-Mendia (1490_CR7) 2008; 6 IY Cho (1490_CR37) 2021; 45 CC Wang (1490_CR42) 2004; 53 SA Sabatino (1490_CR38) 2007; 25 S Hong (1490_CR14) 2020; 18 KJ Jung (1490_CR20) 2015; 242 O Vardeny (1490_CR31) 2013; 1 AC Vasques (1490_CR8) 2011; 93 A Kalogeropoulos (1490_CR33) 2009; 15 MK Kim (1490_CR39) 2017; 16 KM Sturgeon (1490_CR3) 2019; 40 PT Bradshaw (1490_CR4) 2016; 27 Y Zhao (1490_CR30) 2021; 47 KW Jung (1490_CR34) 2019; 51 B Park (1490_CR26) 2020; 19 A Wang (1490_CR29) 2021; 20 SC Seong (1490_CR17) 2017; 46 LS Mehta (1490_CR6) 2018; 137 U Campia (1490_CR5) 2019; 139 A Di Pino (1490_CR40) 2019; 40 S Li (1490_CR13) 2019; 9 TH Park (1490_CR21) 2016; 12 SB Lee (1490_CR11) 2018; 17 F Guerrero-Romero (1490_CR43) 2010; 95 MH Jung (1490_CR18) 2020; 63 Q Zhao (1490_CR28) 2021; 28 M Wamil (1490_CR32) 2021; 44 SH Khan (1490_CR44) 2018; 10 N Barzegar (1490_CR24) 2020; 19 JC Youn (1490_CR2) 2020; 317 KW Nam (1490_CR12) 2020; 19 Q Liu (1490_CR27) 2022; 75 SH Armenian (1490_CR16) 2016; 34 X Tian (1490_CR25) 2021; 20 CE DeSantis (1490_CR1) 2014; 64 D Navarro-Gonzalez (1490_CR9) 2016; 86 FE van Leeuwen (1490_CR36) 2017; 35 SW Yi (1490_CR19) 2021 H Abdel-Qadir (1490_CR15) 2017; 2 GL Vega (1490_CR23) 2014; 62 |
| References_xml | – volume: 93 start-page: e98-e100 issue: 3 year: 2011 ident: 1490_CR8 publication-title: Diabetes Res Clin Pract doi: 10.1016/j.diabres.2011.05.030 – volume: 27 start-page: 6 issue: 1 year: 2016 ident: 1490_CR4 publication-title: Epidemiology doi: 10.1097/EDE.0000000000000394 – volume: 44 start-page: 1877 issue: 8 year: 2021 ident: 1490_CR32 publication-title: Diabetes Care doi: 10.2337/dc21-0429 – volume: 6 start-page: 299 issue: 4 year: 2008 ident: 1490_CR7 publication-title: Metab Syndr Relat Disord doi: 10.1089/met.2008.0034 – volume: 9 start-page: 7320 issue: 1 year: 2019 ident: 1490_CR13 publication-title: Sci Rep doi: 10.1038/s41598-019-43776-5 – volume: 18 start-page: 361 issue: 1 year: 2020 ident: 1490_CR14 publication-title: BMC Med doi: 10.1186/s12916-020-01824-2 – year: 2021 ident: 1490_CR19 publication-title: Eur J Prev Cardiol. doi: 10.1093/eurjpc/zwab230 – volume: 20 start-page: 46 issue: 1 year: 2021 ident: 1490_CR29 publication-title: Cardiovasc Diabetol doi: 10.1186/s12933-021-01238-1 – volume: 12 start-page: 42 issue: 1 year: 2016 ident: 1490_CR21 publication-title: J Clin Neurol doi: 10.3988/jcn.2016.12.1.42 – volume: 35 start-page: 60 issue: Suppl 1 year: 2017 ident: 1490_CR36 publication-title: Hematol Oncol doi: 10.1002/hon.2402 – volume: 40 start-page: 1447 issue: 6 year: 2019 ident: 1490_CR40 publication-title: Endocr Rev doi: 10.1210/er.2018-00141 – volume: 137 start-page: e30-e66 issue: 8 year: 2018 ident: 1490_CR6 publication-title: Circulation doi: 10.1161/CIR.0000000000000556 – volume: 86 start-page: 99 year: 2016 ident: 1490_CR9 publication-title: Prev Med doi: 10.1016/j.ypmed.2016.01.022 – volume: 95 start-page: 3347 issue: 7 year: 2010 ident: 1490_CR43 publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2010-0288 – volume: 242 start-page: 367 issue: 1 year: 2015 ident: 1490_CR20 publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2015.07.033 – volume: 25 start-page: 2100 issue: 15 year: 2007 ident: 1490_CR38 publication-title: J Clin Oncol doi: 10.1200/JCO.2006.06.6340 – volume: 53 start-page: 2735 issue: 11 year: 2004 ident: 1490_CR42 publication-title: Diabetes doi: 10.2337/diabetes.53.11.2735 – volume: 46 start-page: 799 issue: 3 year: 2017 ident: 1490_CR17 publication-title: Int J Epidemiol – volume: 47 start-page: 101246 issue: 4 year: 2021 ident: 1490_CR30 publication-title: Diabetes Metab doi: 10.1016/j.diabet.2021.101246 – volume: 34 start-page: 1122 issue: 10 year: 2016 ident: 1490_CR16 publication-title: J Clin Oncol doi: 10.1200/JCO.2015.64.0409 – volume: 28 start-page: 1175 issue: 11 year: 2021 ident: 1490_CR28 publication-title: J Atheroscler Thromb doi: 10.5551/jat.59840 – volume: 63 start-page: 1616 issue: 8 year: 2020 ident: 1490_CR18 publication-title: Diabetologia doi: 10.1007/s00125-020-05160-1 – volume: 71 start-page: 7 issue: 1 year: 2021 ident: 1490_CR35 publication-title: CA Cancer J Clin doi: 10.3322/caac.21654 – volume: 139 start-page: e579-e602 issue: 13 year: 2019 ident: 1490_CR5 publication-title: Circulation doi: 10.1161/CIR.0000000000000641 – volume: 42 start-page: 1569 issue: 8 year: 2019 ident: 1490_CR10 publication-title: Diabetes Care doi: 10.2337/dc18-1920 – volume: 46 start-page: 189 issue: 2 year: 2016 ident: 1490_CR22 publication-title: Eur J Clin Invest doi: 10.1111/eci.12583 – volume: 17 start-page: 41 issue: 1 year: 2018 ident: 1490_CR11 publication-title: Cardiovasc Diabetol doi: 10.1186/s12933-018-0692-1 – volume: 317 start-page: 167 year: 2020 ident: 1490_CR2 publication-title: Int J Cardiol doi: 10.1016/j.ijcard.2020.04.080 – volume: 16 start-page: 108 issue: 1 year: 2017 ident: 1490_CR39 publication-title: Cardiovasc Diabetol doi: 10.1186/s12933-017-0589-4 – volume: 75 start-page: 392 issue: 2 year: 2022 ident: 1490_CR27 publication-title: Endocrine doi: 10.1007/s12020-021-02862-3 – volume: 19 start-page: 53 issue: 1 year: 2020 ident: 1490_CR12 publication-title: Cardiovasc Diabetol doi: 10.1186/s12933-020-01031-6 – volume: 62 start-page: 345 issue: 2 year: 2014 ident: 1490_CR23 publication-title: J Investig Med doi: 10.2310/JIM.0000000000000044 – volume: 40 start-page: 3889 issue: 48 year: 2019 ident: 1490_CR3 publication-title: Eur Heart J doi: 10.1093/eurheartj/ehz766 – volume: 19 start-page: 155 issue: 1 year: 2020 ident: 1490_CR24 publication-title: Cardiovasc Diabetol doi: 10.1186/s12933-020-01121-5 – volume: 20 start-page: 19 issue: 1 year: 2021 ident: 1490_CR25 publication-title: Cardiovasc Diabetol doi: 10.1186/s12933-020-01210-5 – volume: 51 start-page: 417 issue: 2 year: 2019 ident: 1490_CR34 publication-title: Cancer Res Treat doi: 10.4143/crt.2019.138 – volume: 2 start-page: 88 issue: 1 year: 2017 ident: 1490_CR15 publication-title: JAMA Cardiol doi: 10.1001/jamacardio.2016.3841 – volume: 15 start-page: 593 issue: 7 year: 2009 ident: 1490_CR33 publication-title: J Card Fail doi: 10.1016/j.cardfail.2009.03.001 – volume: 10 start-page: 74 year: 2018 ident: 1490_CR44 publication-title: Diabetol Metab Syndr doi: 10.1186/s13098-018-0376-8 – volume: 45 start-page: 100615 issue: 1 year: 2021 ident: 1490_CR37 publication-title: Curr Probl Cancer doi: 10.1016/j.currproblcancer.2020.100615 – volume: 113 start-page: 1888 issue: 15 year: 2006 ident: 1490_CR41 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.105.563213 – volume: 64 start-page: 252 issue: 4 year: 2014 ident: 1490_CR1 publication-title: CA Cancer J Clin doi: 10.3322/caac.21235 – volume: 1 start-page: 531 issue: 6 year: 2013 ident: 1490_CR31 publication-title: JACC Heart Fail doi: 10.1016/j.jchf.2013.07.006 – volume: 19 start-page: 210 issue: 1 year: 2020 ident: 1490_CR26 publication-title: Cardiovasc Diabetol doi: 10.1186/s12933-020-01186-2 |
| SSID | ssj0017861 |
| Score | 2.4363003 |
| Snippet | Background
The prevention of subsequent cardiovascular disease (CVD) is an essential part of cancer survivorship care. We conducted the present study to... The prevention of subsequent cardiovascular disease (CVD) is an essential part of cancer survivorship care. We conducted the present study to investigate the... Background The prevention of subsequent cardiovascular disease (CVD) is an essential part of cancer survivorship care. We conducted the present study to... Abstract Background The prevention of subsequent cardiovascular disease (CVD) is an essential part of cancer survivorship care. We conducted the present study... |
| SourceID | doaj pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 52 |
| SubjectTerms | Adult Age Aged Alcohol Angiology Arteriosclerosis Atherosclerosis Biomarkers Blood Glucose Blood pressure Body mass index Cancer Cancer Survivors Cancer therapies Cardio-oncology Cardiology Cardiovascular disease Cardiovascular diseases Cardiovascular Diseases - diagnosis Cardiovascular Diseases - epidemiology Cerebral infarction Cholesterol Codes Cohort analysis Cohort Studies Congestive heart failure Coronary artery disease Data collection Diabetes Family income Fasting Female Glucose Health insurance Heart Failure Hemorrhage High density lipoprotein Humans Insulin Insulin resistance Ischemia Laboratories Lipoproteins Medical screening Medicine Medicine & Public Health Middle Aged Mortality Myocardial infarction Myocardial Infarction - diagnosis Myocardial Infarction - epidemiology Neoplasms - diagnosis Neoplasms - epidemiology Population Population studies Population-based studies Prevention Prospective Studies Risk Assessment Risk Factors Stroke Survival Survivorship Triglycerides |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Lat0wEBUli9JN6btu06JCd42IZT0sd9eEhlBIVw1kJ2w9SCH4hut7C8lX5JM7I8tu3OemW3tsBs2R54xnNEPIW6CgVeQQlnhvIpNeVKzTSrGglEA6waXHH_onn_Xxqfx0ps5ujfrCmrCxPfC4cPsNOOAIPhyg2UrVdKbtwEPVtRBdKTqZOoGCG5uCqZw_qI3m0xEZo_cH9GqYr8QyBNmU7HrhhlK3_t9RzF8rJX9KlyYvdPSA3M_0kX4Y1X5I7oT-Ebl7khPkj8nNreUeaC7CokDy6AbC8IsrB4DzYSpUp6lXIm17T92iLpXmvA0IUKzxpEDo9uCzBmIAkjUdtvCF-bZaD-9pSy_nGWAMfSK8a3UOpJ6mzrVPyOnRxy-HxywPXWBOl_WGNaIJnisfhG5kdMYFgQOtHA_cRKmEQ86Gp1NDcLUvIRZvnRPeV055VYJ9n5KdftWH54RGIWJZuhA7nHAdQ-OlqJ0wnSoDEFNTED7ZwLrckRwHY1zYFJkYbUe7WbCbTXaz1wV5Nz9zOfbj-Kv0AZp2lsRe2ukCIMxmhNl_IawguxMwbN7gg600UF8J7IoX5M18G7Ym5lvaPqy2SabCRK4CmWcjjmZNBM4Ja-qqIPUCYQtVl3f6r-ep_TcwOAF6FmRvwuIPtf68FC_-x1K8JPeqtIkk43qX7GzW2_AKSNmme53233fr6jGA priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB6VIiEuiDeBgoyEuFBDEtt5ICEEiKpCWk6s1JuV2E6LtEq2yW7V9lfwk5nxJimBpddkYjmebzyfM5MZgFdIQeMqwmOJtVnFpRUxLxOluFNKEJ2IpKUP-rPvyeFcfjtSRzswpNv2C9htPdpRP6l5u3h7fnrxEQ3-gzf4LHnXkc-iaCQlGcg85Jevl6ecGktRALbvsnEDbqKzign4M3kVaEizJBr-pdk61MRf-bL-27jovymVf8VVvbs6uAt3ep7JPm2AcQ92XH0fbs36SPoD-PWHXjrWZ2sxZINshW-0uDCITOuGjHbmiyqyorbMTBJYWR_gQQFGyaAMmd8-7n8ohmhqWbfGreisabv3rGDLsVkYJ-eJYzUnuPDMl7h9CPODrz--HPK-OwM3SZiueC5yZyNlnUhyWZnMOEGdr0zkoqySShgid_Qbq3MmtSEe2gtjhLWxUVaFCIRHsFs3tXsCrBKiCkPjqpJaYVcut1KkRmSlCh0y2CyAaNCBNn3pcuqgsdD-CJMleqM3jXrTXm_6MoA34zPLTeGOa6U_k2pHSSq67S807bHubVjnyAUrpJO4SxZS5WVWlDhOmgpRhqKUMoC9ARh6ALKOE-TIEmlYFMDL8TbaMAVmito1ay8TU8RXoczjDY7GmQhqKJancQDpBGGTqU7v1D9PfJ1wpHoC5xnA_oDFq2n9fymeXv8Wz-B27M1D8ijZg91Vu3bPkZetyhfesn4DRQU1uw priority: 102 providerName: Scholars Portal – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1baxUxEA5aQXyRel-tEsE3G9xsLpvtWz1YilCfLPQt7OZChbKnnD1HsL_Cn-xMTnbb1Sr4upmEITOTfLMzmSHkHUDQKnJwS7w3kUkvKtZppVhQSiCc4NLjD_2TL_r4VH4-U2e5TA6-hbkZv-dGfxjwPsJIIyYQyKZkV3fJPQUHL6bvLfRiihjURvPxUcyt82YXT6rPfxuo_DM38rcAabp3jnbJwwwY6eFWwo_IndA_JvdPckj8Cfl5Y4MHmtOuKMA6ugbH--KHAxXzYUxNp6k6Im17T90sE5XmSA0QUMzqpADh9uEgAzJQixUdNnCmfF-uhgPa0sup6xfDWxDWWp4DjKepVu1Tcnr06evimOU2C8zpsl6zRjTBc-WD0I2MzrggsIWV44GbKJVwiNLwPWoIrvYleN-tc8L7yimvSpDoM7LTL_vwgtAoRCxLF2KHPa1jaLwUtROmU2UAKGoKwkcZWJdrkGMrjAubfBGj7VZuFuRmk9zsVUHeT3MutxU4_kn9EUU7UWL17PQBlMpmY7QNgLoIuBCOu1aqpjNtB-vUtRBdKTopC7I3KobNJj3YSgPYlYCneEHeTsNgjBhhafuw3CSaCkO3Cmieb_Vo4kRgZ7CmrgpSzzRsxup8pP92ngp-A2YTwGdB9kddvGbr71vx8v_IX5EHVTIXybjeIzvr1Sa8BsC17t4kS_sFEVokHQ priority: 102 providerName: Springer Nature |
| Title | Associations between the triglyceride-glucose index and cardiovascular disease in over 150,000 cancer survivors: a population-based cohort study |
| URI | https://link.springer.com/article/10.1186/s12933-022-01490-z https://www.ncbi.nlm.nih.gov/pubmed/35429972 https://www.proquest.com/docview/2651948221 https://www.proquest.com/docview/2652028951 https://pubmed.ncbi.nlm.nih.gov/PMC9013459 https://doaj.org/article/9251f929070a459b8ab2937733b03b44 |
| Volume | 21 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMedCentral customDbUrl: eissn: 1475-2840 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017861 issn: 1475-2840 databaseCode: RBZ dateStart: 20020101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1475-2840 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017861 issn: 1475-2840 databaseCode: KQ8 dateStart: 20020101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1475-2840 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017861 issn: 1475-2840 databaseCode: KQ8 dateStart: 20020401 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1475-2840 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017861 issn: 1475-2840 databaseCode: DOA dateStart: 20020101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVEBS databaseName: EBSCOhost Academic Search Ultimate customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 1475-2840 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017861 issn: 1475-2840 databaseCode: ABDBF dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1475-2840 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017861 issn: 1475-2840 databaseCode: DIK dateStart: 20020101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1475-2840 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017861 issn: 1475-2840 databaseCode: GX1 dateStart: 20020101 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1475-2840 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017861 issn: 1475-2840 databaseCode: M~E dateStart: 20020101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1475-2840 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017861 issn: 1475-2840 databaseCode: RPM dateStart: 20020101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1475-2840 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017861 issn: 1475-2840 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1475-2840 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017861 issn: 1475-2840 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 1475-2840 dateEnd: 20250131 omitProxy: true ssIdentifier: ssj0017861 issn: 1475-2840 databaseCode: M48 dateStart: 20020401 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal – providerCode: PRVAVX databaseName: Springer Nature HAS Fully OA customDbUrl: eissn: 1475-2840 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017861 issn: 1475-2840 databaseCode: AAJSJ dateStart: 20021201 isFulltext: true titleUrlDefault: https://www.springernature.com providerName: Springer Nature – providerCode: PRVAVX databaseName: Springer Nature Open Access Journals customDbUrl: eissn: 1475-2840 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017861 issn: 1475-2840 databaseCode: C6C dateStart: 20021201 isFulltext: true titleUrlDefault: http://www.springeropen.com/ providerName: Springer Nature |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9wwEBZtAqWX0nedposKvTUmlvWw3EvZLAlhYUNpG9ibsSU5KQR7u94NNL-iP7kzWtnp9pGLDfbYSJ7XJ814hpB3AEHTmsGyxFpdx8LyNK6UlLGTkiOcYMLihv7sTJ2ei-lczsOGWxfSKnub6A21bQ3ukR-mCrCGAHfGPi6-x9g1CqOroYXGfbLLAKqgVGfzYcHFMq1Y_6OMVocd-jaMWmIygsiT-GbLGfma_f8Cmn_nS_4RNPW-6OQxeRRAJB1vuP6E3HPNU_JgFsLkz8jP3z56R0MqFgWoR1cwo6sfBsTOuj5dnfqKibRsLDVb2ak0RG-AgGKmJwVYdwDGDchAVJa0W4OduW6X3Qda0sXQCSxGzwjvai8B2lNfv_Y5OT85_jo5jUPrhdioJFvFOc-dZdI6rnJRG20cx7ZWhjmmayG5QeSG_6g6ZzKbwIq8NIZbmxppZQJcfkF2mrZxrwitOa-TxLi6wj7Xtcut4JnhupKJA3iqI8J6HhQm1CXH9hhXhV-faFVs-FYA3wrPt-ImIu-HZxabqhx3Uh8hawdKrKjtL7TLiyIoaJED0KtBhMAElkLmlS4reE-WcV4lvBIiIvu9YBRBzbviVigj8na4DQqKUZeyce3a06QYzpVA83IjR8NIOHYLy7M0ItmWhG0NdftO8-3SFwEHHMdhnBE56GXxdlj__xR7d8_iNXmYevUQMVP7ZGe1XLs3ALpW1chr1ojsjsfTL1M4Hx2fffoMVydqMvIbGXCcCf0LRXMwlQ |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELaqIgEXxLuBAkaCE7Uax3YeSAjxqra021Mr7c0ktkORqmTZ7ILaX8Ev4Tcy4zxKePTW62YSeTPjb77JjGcIeQYUNCo5hCXWpiWTVkSsiJViTimBdIJLix_0pwfx5Eh-nKnZGvnZn4XBssoeEz1Q29rgN_LtKAauIcGd8dfzrwynRmF2tR-h0ZrFnjv9DiFb82r3Pej3eRTtfDh8N2HdVAFm4jBZskxkznJlnYgzWZrUOIETmwx3PC2lEgZJCR6_dM4kNoRgMzdGWBsZZVUosNEBQP4VKUKJvfqT2RDg8SSNeX8wJ423G_SlmCXF4geZhexs5Pz8jIB_Edu_6zP_SNJ637dzk9zoSCt901rZLbLmqtvk6rRLy98hP35TckO70i8K1JIu4Q2enBowc-v68njqOzTSvLLUjKphaZctAgGKlaUUaOQWgCmIgWkuaLMCXPtWL5qXNKfzYfIYQ08Mz6qPIZSgvl_uXXJ0KUq5R9arunIbhJZClGFoXFngXO3SZVaKxIi0UKEDOpwGhPc60Kbrg47jOE60j4fSWLd606A37fWmzwLyYrhn3nYBuVD6Lap2kMQO3v6HevFZd4CgMyCWJXBTgNxcqqxI8wKekyRCFKEopAzIZm8YuoOVRp9vgoA8HS4DIGCWJ69cvfIyEaaPFcjcb-1oWInA6WRZEgUkGVnYaKnjK9WXY990HHijgHUGZKu3xfNl_f9VPLj4Xzwh1yaH0329v3uw95Bcj_xWkYzHm2R9uVi5R0D4lsVjv8so-XTZ2_oXsqpnvQ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Zb9QwEB5BK1W8IG4CBYzEG42axEcc3pZjVRZaIUGlvlmJjxapSlabXST6K_jJjJ2DBgoSr_HYsjwz9jeZC-AFQtDMpWiWGCNdzAzN4kpwHlvOqYcTKTP-h_7hkTg4ZosTfnIpiz9Euw8uyS6nwVdpqtf7S-M6FZdiv_WvlPc_-rACViTxxXXYlrwQaH5tz2aLz4vRk5BLkQ7JMlfOnDxIoW7_VWDzz5jJ3xyn4T2a34KbPZAks47zt-Gare_AzmHvKr8LPy4dfEv6cCyCcI-s0SA__65R9IwdQtZJqJpIytoQPYlQJb0HBwmIj_YkCO328IJDMhSXFWk3eNd8a1btK1KS5dgNLPavI67VnCG8J6GG7T04nr_78uYg7tsvxFok-TouaGFNyo2lomBOS22pb22lU5tKxzjVHr35PFVrdW4StMpLrakxmeaGJ8jp-7BVN7V9CMRR6pJEW1f5XtfOFobRXFNZ8cQiRJURpAMPlO5rk_sWGecq2ChSqI5vCvmmAt_URQQvxznLrjLHP6lfe9aOlL6qdvjQrE5Vr6SqQLDnEC_iNVgyXlSyrHCdPKe0SmjFWAS7g2CoXtVblQkEwQxxVhrB83EYldR7XsraNptAk3mXLkeaB50cjTuhvmNYkWcR5BMJm2x1OlJ_PQuFwBHLUdxnBHuDLP7a1t-P4tH_kT-DnU9v5-rj-6MPj-FGFjSHxanYha31amOfICZbV097tfsJQn8wyA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Associations+between+the+triglyceride-glucose+index+and+cardiovascular+disease+in+over+150%2C000+cancer+survivors%3A+a+population-based+cohort+study&rft.jtitle=Cardiovascular+diabetology&rft.au=Mi-Hyang+Jung&rft.au=Sang-Wook%2C+Yi&rft.au=An%2C+Sang+Joon&rft.au=Jee-Jeon+Yi&rft.date=2022-04-16&rft.pub=BioMed+Central&rft.eissn=1475-2840&rft.volume=21&rft.spage=1&rft_id=info:doi/10.1186%2Fs12933-022-01490-z |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1475-2840&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1475-2840&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1475-2840&client=summon |